Trends to look out for this upcoming year
LaunchBio recently polled our partners to gather their insights on the trends that will shape biotech and life sciences in 2025. From AI-driven breakthroughs and evolving talent strategies to advancements in procurement and lab design, their predictions highlight an industry poised for growth and transformation. The perspectives below reflect the challenges and opportunities that lie ahead as companies navigate a rapidly changing landscape. Learn from our trusted partners on how to prepare for what’s next and what innovations they believe will define the year to come.
Now that the election season is behind us in the USA and companies have mostly run out of their wait-and-see runway, 2025 will likely see an unprecedented return to growth for the majority of Life Science sectors. Companies who had talent retention or talent acquisition struggles in 2024 will see those problems rise to critical levels in the second half of 2025 as investment dollars, which have been mostly sidelined for the past 2 years, return to the industry and create an increasing demand for talent. Most companies will have to turn to both (a) outsourced Pharma Services and (b) upskilling AI tools in much bigger and bolder ways than previously planned. Lastly, the recent struggles of tail spinning, waiting, and disappointment will be replaced with forward progress, green lights for new programs, and – well – FUN!
Stephen M. Perry, CEO and Founder of Kymanox
In the year ahead, biotech and life sciences will experience a growing shift toward procurement automation and data-driven decision-making, helping organizations optimize budgets and streamline operations. Anticipated regulatory changes focusing on supply chain transparency will drive companies to enhance visibility into sourcing practices and ensure vendor compliance. To meet these evolving requirements, procurement teams must adopt more robust systems and processes that balance efficiency with regulatory adherence. Prendio-BioProcure is well-equipped to support this transformation, providing tailored procurement solutions designed to simplify workflows and empower biotech companies to thrive in a highly regulated environment.
Valerie Podbelski, Director of Growth Marketing, Prendio
The use of data science including artificial intelligence (AI), and machine learning frameworks have already shown promising results across each stage of the drug development process. The use of these technologies can help optimize drug screening methods and streamline clinical trials through their ability to analyze and process large volumes of data. In addition, utilizing these technologies is expected to make research and development more cost-effective. We expect to see an increase in the use of computer-aided drug design, as well as increased investment in AI based healthcare/biotechnology companies, as most experts are forecasting a significant increase in the size of the AI healthcare/biotechnology market in 2025 and beyond.
Tom Fagley, Partner, Audit & Assurance, EisnerAmper LLP
The Longfellow Real Estate Partners team is looking forward to continuing our support of key life science markets and talent throughout the world. As we look into 2025, we are building the labs of the future that will be fast and nimble to empower the outside innovations that positively influence the life science and bio innovation sectors.
Longfellow Real Estate Partners
Join LaunchBio in 2025 as we continue to foster connections, curate programs and activate sites to foster innovation and drive growth. Sign up for our newsletter to be the first to know or follow us on LinkedIn.